SCHEMBL4862703

SCHEMBL4862703

CCOC(=O)c1nc2ccoc2nc1SC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 1/20 0.42
ALDH1A1 P00352 6/20 0.39
L3MBTL1 Q9Y468 5/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
TARBP2 Q15633 5/20 0.39
CYP1A2 P05177 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
PDCD4 Q53EL6 1/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
XBP1 P17861 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859649 0.85 RXFP1 (0.39) ALDH1A1L3MBTL1KDM4EGAATDP1
SCHEMBL4857813 0.82 GLP1R (0.42) GLP1RALDH1A1L3MBTL1KDM4ETARBP2
SCHEMBL4860361 0.80 MAPT (0.38) ALDH1A1L3MBTL1KDM4ETDP1HSD17B10
SCHEMBL4855010 0.80 TARBP2 (0.42) GLP1RALDH1A1L3MBTL1KDM4EGAA
SCHEMBL6630923 0.80 RXFP1 (0.36) ALDH1A1L3MBTL1KDM4ETDP1HPGD
SCHEMBL4861845 0.74 GLP1R (0.36) GLP1RALDH1A1L3MBTL1TARBP2CYP1A2
SCHEMBL6210186 0.71 MAPT (0.32) ALDH1A1TDP1MAPTMAPK1
SCHEMBL10402795 0.70 TSHR (0.45) GLP1RALDH1A1KDM4EGAATARBP2
SCHEMBL4854555 0.70 ALDH1A1 (0.36) ALDH1A1KDM4EGAACYP1A2HSD17B10
SCHEMBL10403477 0.69 TSHR (0.46) ALDH1A1KDM4EGAATARBP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456192-B2 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof PIERRE FABRE MEDICAMENT (FR) 2008-11-25 US disclosed
EP-1440075-B1 NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF PF MEDICAMENT (FR) 2005-06-08 EP disclosed
US-20050080085-A1 Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof PIERRE FABRE MEDICAMENT (FR) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080085-A1 Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof AOC3, MAOB, AOC1 GLP1R 264/4885ALDH1A1 1130/4885L3MBTL1 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.